

1651
grw



LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP

2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnlech@synnlech.com
www.synnlech.com

July 23, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of D. Huang and D. Qi
Application No. 09/910,887
Filed July 24, 2001


Examiner S. Qazi
Group Art Unit 1651

NOVEL AGLYCON DAMMARANE SAPOGENINS, THEIR USE
AS ANTI-CANCER AGENTS, AND A PROCESS FOR PRODUCING
SAME

(Attorney Docket No. P27,199 USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence, along with any other papers indicated as being enclosed, is being deposited with the United States Postal Services, as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on July 23, 2004.


Janet M. Karmann

Mail Stop: Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(B)

Sir:

It is requested respectfully that the information identified on the enclosed Form PTO-1449 (Modified) be made of record and considered with respect to the above-referenced patent application. The Examiner is requested to indicate that each item on

Group Art Unit 1651
Application No. 09/910,887

July 23, 2004
Docket No. P27,199 USA


the enclosed Form PTO-1449 (Modified) has been considered by initialing and dating the enclosed Form and returning a copy of same to the undersigned.

This Information Disclosure Statement is filed before a first Office Action on the merits after the filing of a Request for Continued Examination. Each item identified in this Information Disclosure Statement was first cited in the Written Opinion mailed April 1, 2004 (copy enclosed) for counterpart application number SG 200301269-7. The undersigned hereby certifies that the Written Opinion and all of the art being cited were brought to the attention of a person having a duty of disclosure within 30 days of the filing date of the within Information Disclosure Statement

Identification of information on the attached Form, or in this statement, is not an admission that such information is prior art to the invention claimed in the present application or that such information is in an analogous art area.


The Commissioner is authorized hereby to charge any fees or credit any overpayment associated with this Statement (copy enclosed) to Deposit Account Number 19-5425.

Respectfully submitted,



Peter J. Butch III, Esq.
Registration No. 32,203

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Telephone (215) 923-4466
Facsimile (215) 923-2189



FORM PTO 21449 (MODIFIED)
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.	09/910,887
FILING DATE	July 24, 2001
FIRST NAMED INVENTOR	D. Huang et al.
ART UNIT	1651
EXAMINER NAME	S. Qazi
ATTORNEY DOCKET NO.	P27,199 USA

OTHER PUBLICATIONS

AA	Kwon et al., <i>Journal of Chromatography</i> , 921(2): 335-339 (2001)
AB	
AC	

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation *and* not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

July 23, 2004